FI963393A0 - Syöpäolosuhteiden määritys MAGE-geeni-ilmennyksellä - Google Patents

Syöpäolosuhteiden määritys MAGE-geeni-ilmennyksellä

Info

Publication number
FI963393A0
FI963393A0 FI963393A FI963393A FI963393A0 FI 963393 A0 FI963393 A0 FI 963393A0 FI 963393 A FI963393 A FI 963393A FI 963393 A FI963393 A FI 963393A FI 963393 A0 FI963393 A0 FI 963393A0
Authority
FI
Finland
Prior art keywords
determination
gene expression
cancer conditions
mage gene
mage
Prior art date
Application number
FI963393A
Other languages
English (en)
Swedish (sv)
Other versions
FI963393A (fi
Inventor
Plaen Etienne De
Thierry Boon-Falleur
Bernard Lethe
Jean-Pierre Szikora
Smet Charles De
Patrick Chomez
Beatrice Gaugler
Den Eynde Benoit Van
Francis Brasseur
Jean-Jacques Patard
P Weynants
M Marchand
Der Bruggen Pierre Van
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/204,727 external-priority patent/US5512437A/en
Priority claimed from US08/209,172 external-priority patent/US5763165A/en
Priority claimed from US08/299,849 external-priority patent/US5612201A/en
Priority claimed from US08/346,774 external-priority patent/US5512444A/en
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Publication of FI963393A publication Critical patent/FI963393A/fi
Publication of FI963393A0 publication Critical patent/FI963393A0/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Saccharide Compounds (AREA)
FI963393A 1994-03-01 1996-08-30 Syöpäolosuhteiden määritys MAGE-geeni-ilmennyksellä FI963393A0 (fi)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/204,727 US5512437A (en) 1994-03-01 1994-03-01 Method for determining head and neck squamous cell carcinomas, prostate carcinomas, and bladder tumors by assaying for mage-3
US08/209,172 US5763165A (en) 1994-03-10 1994-03-10 Method for determining lung adenocarcinomas by assaying for one or more of MAGE-1, MAGE-2 and MAGE-3
US08/299,849 US5612201A (en) 1991-05-23 1994-09-01 Isolated nucleic acid molecules useful in determining expression of a tumor rejection antigen precursor
US08/346,774 US5512444A (en) 1994-03-01 1994-11-30 Method for determining bladder tumors by assaying for MAGE-1,2,3 or 4
PCT/US1995/002203 WO1995023874A1 (en) 1994-03-01 1995-02-23 Determination of cancerous conditions by mage gene expression

Publications (2)

Publication Number Publication Date
FI963393A FI963393A (fi) 1996-08-30
FI963393A0 true FI963393A0 (fi) 1996-08-30

Family

ID=27498545

Family Applications (1)

Application Number Title Priority Date Filing Date
FI963393A FI963393A0 (fi) 1994-03-01 1996-08-30 Syöpäolosuhteiden määritys MAGE-geeni-ilmennyksellä

Country Status (11)

Country Link
EP (1) EP0871765B1 (fi)
JP (1) JPH09509832A (fi)
KR (1) KR100316209B1 (fi)
AT (1) ATE209690T1 (fi)
AU (1) AU698310B2 (fi)
CA (1) CA2184482A1 (fi)
DE (1) DE69524264T2 (fi)
FI (1) FI963393A0 (fi)
NO (1) NO963589L (fi)
NZ (1) NZ282536A (fi)
WO (1) WO1995023874A1 (fi)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5908778A (en) * 1996-10-03 1999-06-01 Ludwig Institute For Cancer Research Mage-10 encoding cDNA, the tumor rejection antigen precursor mage-10, antibodies specific to the molecule, and uses thereof
US6221593B1 (en) * 1996-10-03 2001-04-24 Ludwig Institute For Cancer Research Method for determining cancer by determining expression of MAGE-10
CA2285688A1 (en) 1997-04-11 1998-10-22 Peter Kufer Novel primers and methods for the detection of disseminated tumor cells
US6027924A (en) * 1997-04-25 2000-02-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecule coding for tumor rejection antigen precursor MAGE-C1 and uses thereof
WO1999004265A2 (en) * 1997-07-17 1999-01-28 Ludwig Institute For Cancer Research Cancer associated nucleic acids and polypeptides
DK1659179T3 (da) 1998-02-05 2011-10-10 Glaxosmithkline Biolog Sa Tumor-associerede antigenderivater fra MAGE-familien og nucleinsyresekvenser kodende for dem anvendt til fremstilling af fusionsproteiner og sammensætninger til vaccination
US6686147B1 (en) 1998-07-15 2004-02-03 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor
CA2340592A1 (en) * 1998-08-31 2000-03-09 Urogenesys, Inc. Phelix: a testis-specific protein expressed in cancer
US6733998B1 (en) * 1998-12-07 2004-05-11 Sloan-Kettering Institute For Cancer Research Micromonospora echinospora genes coding for biosynthesis of calicheamicin and self-resistance thereto
US6475794B1 (en) * 1999-10-08 2002-11-05 The Johns Hopkins University Converting diploidy to haploidy for genetic diagnosis
EP1377680B1 (en) 2001-04-12 2011-10-05 Imperial Innovations Limited Diagnosis and treatment of breast cancer based upon scn5a
GB0612342D0 (en) * 2006-06-21 2006-08-02 Glaxosmithkline Biolog Sa Method
GB201120860D0 (en) 2011-12-05 2012-01-18 Cambridge Entpr Ltd Cancer immunotherapy
WO2016094309A1 (en) 2014-12-10 2016-06-16 Myosotis Inhibition of tnf signaling in cancer immunotherapy
KR20210089270A (ko) 2015-07-16 2021-07-15 바이오카인 테라퓨틱스 리미티드 암 치료용 조성물 및 방법
GB201519340D0 (en) 2015-11-02 2015-12-16 Cambridge Entpr Ltd Methods of T-lymphocyte expansion
GB201519481D0 (en) 2015-11-04 2015-12-16 Cancer Rec Tech Ltd Immunomodulatory antibodies
GB201616238D0 (en) 2016-09-23 2016-11-09 Adaptimmune Ltd Modified T cells
WO2018127919A1 (en) 2017-01-05 2018-07-12 Kahr Medical Ltd. A SIRP1 alpha-41BBL FUSION PROTEIN AND METHODS OF USE THEREOF
RU2769513C2 (ru) 2017-01-05 2022-04-01 Кахр Медикал Лтд. Слитый белок pd1-4-1bbl и способы его применения
GB201700345D0 (en) 2017-01-09 2017-02-22 F-Star Beta Ltd Conditional agonists of immune responses
IL250916A0 (en) 2017-03-02 2017-06-29 Geiger Benjamin Methods for growing t cells in culture and their use
WO2019006003A1 (en) 2017-06-27 2019-01-03 The Trustees Of Princeton University COMPOSITIONS AND METHODS FOR IMPROVING IMMUNOTHERAPY
GB201713078D0 (en) 2017-08-15 2017-09-27 Adaptimmune Ltd T Cell Modification
AU2019211121A1 (en) 2018-01-26 2020-08-27 Cambridge Enterprise Limited Peptide exchange protein
US20210214417A1 (en) 2018-07-11 2021-07-15 Kahr Medical Ltd. SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
GB201811410D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
US20210379109A1 (en) 2018-08-24 2021-12-09 The Trustees Of Princeton University Immunotherapy with metabolic enzyme expression
GB201820444D0 (en) 2018-12-14 2019-01-30 Adaptimmune Ltd Marker for T cell expansion
CA3146248A1 (en) 2019-07-11 2021-01-14 Kahr Medical Ltd. Heterodimers and methods of use thereof
GB201911954D0 (en) 2019-08-20 2019-10-02 Adaptimmune Ltd Lentiviral transduction methods
WO2021137231A1 (en) 2019-12-31 2021-07-08 Kahr Medical Ltd. Methods of culturing t cells with a 4-1bbl fusion polypeptide and uses of same
US20230048361A1 (en) 2019-12-31 2023-02-16 Kahr Medical Ltd. Methods of culturing t cells and uses of same
IL276599A (en) 2020-08-09 2022-03-01 Yeda Res & Dev T cell receptor unique to mage-a1 and its uses

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1

Also Published As

Publication number Publication date
KR100316209B1 (ko) 2002-06-26
DE69524264T2 (de) 2002-07-18
JPH09509832A (ja) 1997-10-07
NO963589D0 (no) 1996-08-28
WO1995023874A1 (en) 1995-09-08
FI963393A (fi) 1996-08-30
AU1968295A (en) 1995-09-18
CA2184482A1 (en) 1995-09-08
NZ282536A (en) 1998-07-28
EP0871765B1 (en) 2001-11-28
KR970701790A (ko) 1997-04-12
AU698310B2 (en) 1998-10-29
EP0871765A1 (en) 1998-10-21
NO963589L (no) 1996-10-31
DE69524264D1 (de) 2002-01-10
ATE209690T1 (de) 2001-12-15
EP0871765A4 (en) 1999-08-11

Similar Documents

Publication Publication Date Title
FI963393A0 (fi) Syöpäolosuhteiden määritys MAGE-geeni-ilmennyksellä
CA2137822A1 (en) Method for detecting pre-cancerous or cancerous cells using p90 antibodies or probes
ATE371721T1 (de) Tiermodelle für die menschliche prostatakrebsfortschreitung
FR2734069B1 (fr) Methode pour predire, par une technique d'inversion, l'evolution de la production d'un gisement souterrain
DE3574730D1 (de) Monoklonaler antikoerper gegen ein humanes tumor-karzinom-assoziiertes antigen.
IT8223932A0 (it) Rivelazione di tumori con anticorpi monoclonali radiomarcati.
AU588542B2 (en) Immunoassay for breast cancer employing monoclonal antibodies
DE69535002D1 (de) Rekombinante humanisierte antikörper gegen fb5
NO870770L (no) FremgangsmŸte for fremstilling av monoklonale antistoffer.
ES2071833T3 (es) Agente para neutralizar la actividad procoagulante asociada a celulas tumorales.
DE3586216D1 (de) Brusttumorassoziiertes antigen und monoklonale antikoerper dazu.
HK1008228A1 (en) Isolated, truncated nucleic acid molecules which code for gage tumor rejection antigen
NO970030L (no) Isolert nukleinsyresekvens som koder for et tumor-rejeksjonsantigen presentert av HLA-A2
SE9500030D0 (sv) Method of determining metastatic potential of tumor cells
FR2714915B1 (fr) Fragment de gène, etc, d'un anticorps reconnaissant une mucine spécifique de cancers .
ZA902425B (en) Retinoblastoma gene product and uses therefor
WO1996029409A3 (en) Rage tumor rejection antigens
FR2720277B1 (fr) Méthode de traitement des cancers par régulation de la protéine P53.
PT825256E (pt) Celula hibrida e a sua utilizacao para a producao de um farmaco para a inducao de uma imunidade tumoral
EP0161000A3 (en) Human suppressor factors and method of using them
AU4403096A (en) Method of diagnosing presence of malignant tumour
SE8402957L (sv) Formstag till gjutveggsformar
HUP9904404A1 (hu) Eljárás laphám-karcinómák diagnosztizálására és kezelésére
IL60664A0 (en) Monoclonal antibodies and assay for the detection of breast cancer
SE8402537L (sv) Lock till matberedningskerl